Navigation Links
TOPICA Announces Positive Phase 2 Clinical Results for Luliconazole, a Potent Topical Antifungal
Date:10/6/2009

PALO ALTO, Calif., Oct. 6 /PRNewswire/ -- TOPICA Pharmaceuticals, a privately-held biotechnology company, today announced positive results from its Phase 2 clinical study evaluating luliconazole, one of the most potent and broad spectrum topical antifungal agents, in patients with tinea pedis (athlete's foot). The study was designed to assess the effectiveness of 1% luliconazole cream applied once daily for 14 days compared with once daily for 28 days. The study met its primary efficacy endpoint demonstrating that luliconazole, when applied once daily for 14 days, was able to achieve "complete clearance," as evaluated by a clear clinical score and negative mycology assessment (negative fungal culture and negative potassium hydroxide (KOH) test) equivalent to the 28-day dosing regimen.

"These Phase 2 results suggest that luliconazole may be able to treat tinea pedis in half the time, compared with commonly prescribed products in the U.S., which require treatment once or twice a day for four weeks. For tinea pedis patients, these results may translate to a significantly easier treatment plan to follow, which should improve clinical outcomes. It is impressive to see that even four weeks after treatment ends with luliconazole, its antifungal effects continued to persist," said Terry M. Jones, M.D., a board certified dermatologist and leading enroller in the phase 2 trial.

The multi-center, randomized, double blind, trial evaluated the safety and optimal duration of 1% luliconazole cream administered once daily for 14 or 28 days in patients with moderate to severe tinea pedis. The Phase 2 results demonstrated:

  • At day 42, the 14-day dose resulted in a 53.7 percent complete clearance rate compared with a placebo rate of 4.5 percent (p=0.0001);
  • At day 42, the 28-day dose resulted in a 45.7 percent complete clearance rate compared with a placebo rate of 10 percent (p=0.0071);
  • There was no statistical differ
    '/>"/>

SOURCE TOPICA Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Helix BioPharma Provides Updates on Topical Interferon Alpha-2b and L-DOS47 Following Pre-IND Meetings With the U.S. FDA
2. ProFibrix Initiates Phase II Clinical Trial of its Lead Topical Hemostat Product Fibrocaps(TM)
3. Arcion Therapeutics Topical Pain Candidate, ARC-4558, Significantly Reduces Pain Caused by Diabetic Neuropathy
4. Fast-Acting, Long-Lasting Topical Relief From Arthritis Pain
5. NovaBay Pharmaceuticals Announces Lead Anti-infective Product Candidate, NVC-422, Shown to be Effective in Treating Topical Fungal Infection
6. ISTA Pharmaceuticals Announces Phase III Results for Once-Daily Topical Xibrom(TM) 0.09%
7. Pharmos Announces Clinical Results from Phase 2a Trial of Topical Diclofenac NanoEmulsion Cream
8. Topical Treatment for Cold Sores Achieves Efficacy of Oral Drugs; Represents Paradigm Shift in the Treatment of Skin Infections
9. NanoBio Demonstrates New Topical Approach to Treating Nail Fungus That Circumvents Problems with Current Therapy
10. Helix Receives Approval to Open Sites in Germany for its Ongoing Clinical Trial With Topical Interferon Alpha-2b in Patients With Ano-Genital Warts
11. ImQuest Receives Two Year Phase 2 SBIR Grant to Develop Pyrimidinedione Product as an Anti-HIV Topical Microbicide
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... 2014 Research and Markets ( http://www.researchandmarkets.com/research/tjlw9k/immunoprotein ... "Immunoprotein Diagnostic Testing Market - Forecasts to 2019: ... 6% and is expected to be valued at ... http://photos.prnewswire.com/prnh/20130307/600769 ... been segmented according to immunoprotein types which include ...
(Date:7/10/2014)... 2014  Major advances in radiation therapy and ... highlighted in a three-day Oncology Summit taking place ... 2014.  Renowned national and international cancer experts from seven ... exchange knowledge on modern technologies making treatment for ... The Summit will address a wide ...
(Date:7/10/2014)... 2014 Integrated Silicon Solution, Inc. (Nasdaq: ... analog IC solutions, today announced that it will host ... at 7:00 a.m. Pacific Time (10:00 a.m. Eastern Time) ... 2014 third quarter ended June 30, 2014. ... before 6:50 a.m. Pacific time on July 24, 2014.  ...
Breaking Medicine Technology:Immunoprotein Diagnostic Testing Market - Forecasts to 2019: Expected to grow at the highest CAGR of 6% and is expected to be valued at USD 4,943.0 million 2Improving quality and access to advanced cancer care in India and South Asia 2Improving quality and access to advanced cancer care in India and South Asia 3Improving quality and access to advanced cancer care in India and South Asia 4Improving quality and access to advanced cancer care in India and South Asia 5
... DENVER, Nov. 12 Corgenix Medical Corporation (OTC Bulletin Board: ... today reported sales of $2,044,967 for the first fiscal quarter ... ended September 30, 2008, an increase of 2.2%. , The ... compared with an operating loss of $94,133 for the first ...
... WASHINGTON, Nov. 12 Women,s Health Weekly recently ... are working on nearly 1,000 life-changing medicines for diseases affecting ... the Pharmaceutical Research and Manufacturers of America ... Food and Drug Administration or are in human clinical trials. ...
Cached Medicine Technology:Corgenix Reports Financial Results for First Quarter of Fiscal 2010 2Corgenix Reports Financial Results for First Quarter of Fiscal 2010 3Record Number of New Medicines in Development for Women 2
(Date:7/11/2014)... (PRWEB) July 11, 2014 Utilizing the ... own, Dr. William Koenig, has topped a record number ... he has performed over 400 successful procedures without the ... Koenig is well known across the country for his ... safety record has long been the foundation for numerous ...
(Date:7/11/2014)... News) -- Children who have emergency surgery on ... potentially even death than those who have weekday ... the Johns Hopkins researchers noted that the risk ... data on nearly 440,000 simple emergency surgeries that ... 22-year period. The surgeries are considered generally ...
(Date:7/11/2014)... The report “Probiotics Market by Products (Functional Foods, ... Therapeutic, Preventive Health Care) & Ingredients (Lactobacilli, Bifidobacteria, ... ” defines and segments the global probiotics market ... value of probiotic products and ingredients. The report ... the global market with an analysis of trends, ...
(Date:7/11/2014)... (PRWEB) July 11, 2014 Global enterprises ... services to outsource day-to-day management activities. Managed services offer ... additional expenses. The economic slowdown resulted into rising operational ... and expenses is considered to be the global market ... future. , The global managed services market is estimated ...
(Date:7/11/2014)... As reported by the New York ... significant number of severe adverse events such as renal ... death from the highly-promoted and costly immune-system drug, Acthar, ... report , a regulatory filing revealed that the total ... almost 14% of prescriptions, up from 9.1% in 2011. ...
Breaking Medicine News(10 mins):Health News:Rochester Surgeon Hits Milestone with Keller Funnel 2Health News:Emergency Surgeries on Weekends Riskier for Kids: Study 2Health News:Probiotic Ingredient Market worth $1,732.8 Million by 2019 - A Report by MarketsandMarkets 2Health News:Probiotic Ingredient Market worth $1,732.8 Million by 2019 - A Report by MarketsandMarkets 3Health News:Probiotic Ingredient Market worth $1,732.8 Million by 2019 - A Report by MarketsandMarkets 4Health News:Probiotic Ingredient Market worth $1,732.8 Million by 2019 - A Report by MarketsandMarkets 5Health News:North America Managed Services Market Worth $68.65 Billion by 2018 - New Report by MicroMarket Monitor 2Health News:North America Managed Services Market Worth $68.65 Billion by 2018 - New Report by MicroMarket Monitor 3Health News:North America Managed Services Market Worth $68.65 Billion by 2018 - New Report by MicroMarket Monitor 4Health News:Acthar’s Deadly Adverse Events Revealed 2Health News:Acthar’s Deadly Adverse Events Revealed 3
... , SUNDAY, June 5 (HealthDay News) -- The human ... that stores calories and the "good" brown kind that burns ... make more brown fat to help people lose weight. ... be used for treating obesity and diabetes," study lead author ...
... -- ASCO Abstract #CRA9015. Flaxseed provides no benefit in ... and postmenopausal women, according to a Mayo Clinic ... (NCCTG) study. The randomized, placebo-controlled study was conducted on ... no statistically significant difference in mean hot flash scores ...
... children who had cancer, with follow-up of about 25 years, ... (a new tumor) at older than age 40 years was ... urinary tract organs), according to a study in the June ... cancer. The study is being published early online to coincide ...
... that the worse a woman,s skin wrinkles are during the ... is. The results will be presented Monday at The Endocrine ... the appearance of the skin may offer a glimpse of ... Pal, MD, a reproductive endocrinologist and associate professor at Yale ...
... , FRIDAY, June 3 (HealthDay News) -- U.S. health officials ... the deadly new strain of E. coli bacteria affecting Germany ... "This outbreak has not affected the U.S.," David ... Operations, said during a Friday afternoon news conference. ...
... mutant gene long thought to accelerate tumor growth in ... cells, showing promise for novel cancer therapies, a Mayo ... presented by Mayo Clinic researcher Honey Reddi, Ph.D., at ... discovery could have widespread implications in cancer research and ...
Cached Medicine News:Health News:Brown Fat Cells May One Day Help Combat Obesity 2Health News:Mayo Clinic: Flaxseed no cure for hot flashes during breast cancer or menopause 2Health News:Childhood cancer survivors at increased risk of certain tumors in middle-age 2Health News:Childhood cancer survivors at increased risk of certain tumors in middle-age 3Health News:Severity of facial wrinkles may predict bone density in early menopause 2Health News:Officials: U.S. Not Affected by European E. Coli Outbreak 2Health News:Officials: U.S. Not Affected by European E. Coli Outbreak 3Health News:Fighting cancer with cancer: Mayo Clinic finds promising use for thyroid cancer gene 2